The Central Drugs Standard Control Organisation (CDSCO) has granted approval for Durvalumab in combination with FLOT ...

AstraZeneca has asked the Supreme Court to hear its case challenging the Medicare Drug Price Negotiation Program created through the Inflation Reduction Act (IRA). According to the Supreme Court’s ...

AstraZeneca is keeping its options over expansion in Cambridge open by submitting fresh plans for a new conference centre and ...

A straZeneca plans to invest $50 billion in its medicine manufacturing and R&D operations across the United States by 2030. The investment is expected to create tens of thousands of new, highly ...

The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's ...

AstraZeneca on Tuesday employed for the first time diversity and inclusion broker-dealers as part of its bond syndicate underwriting a US$2.25bn debt offering, according to bankers and Refinitiv data.

IN A COUNTRY struggling to find reasons for cheer, British life sciences offer a ray of hope. The £108bn ($145bn) industry employs more than 300,000 people, many in high-value jobs, and Britain is a ...

AstraZeneca's ambitious $80 billion revenue goal by 2030 hinges on oncology growth and successful new drug launches, but faces patent expiries and fierce competition. While current financials and ...

AstraZeneca PLC boasts strong 2024 results with $54B revenue and 14 blockbuster drugs, driven by robust growth in oncology and rare disease franchises. Key products like Farxiga, Tagrisso, and ...

AstraZeneca Plc (NASDAQ:AZN) shared on Monday full data from the Bax24 Phase 3 trial of once-daily 2mg baxdrostat versus placebo, on the reduction of ambulatory systolic blood pressure (SBP), as well ...

AstraZeneca strengthens its weight management portfolio through a new strategic collaboration agreement with CSPC ...